E-mail us: service@prospectnews.com Or call: 212 374 2800
Bank Loans - CLOs - Convertibles - Distressed Debt - Emerging Markets
Green Finance - High Yield - Investment Grade - Liability Management
Preferreds - Private Placements - Structured Products
 
Published on 2/23/2006 in the Prospect News Biotech Daily.

Schering AG boosted to outperform by Bear Stearns

Bear Stearns analyst Marietta Miemietz upgraded Schering AG to outperform from peer perform with a price target of €68. The analyst expects to see consensus earnings upgrades as management has guided for a 20% operating margin in 2008, in line with Bear Stearns' forecast and 16% ahead of consensus on earnings per share. Bear Stearns also expects possible strong Betaseron sales in the first quarter of 2006, with a possible Asoprisnil filing. Shares of the Berlin, Germany, pharmaceutical company were up 5 cents, or 0.07%, at $69.57 on volume of 44,900 shares versus the three-month running average of 31,248 shares. (NYSE: SHR)


© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.